Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Goeree

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Social Science & Medicine (1982)|May 1, 1992
The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in CanadaS Sheingold, D Churchill, N Muirhead, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 26, 2001
Economic implications of hip fracture: health service use, institutional care and cost in CanadaM E Wiktorowicz, R Goeree, A Papaioannou, et al.
BMC Research Notes|June 18, 2015
Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluationsB Tsoi, D O'Reilly, J Jegathisawaran, et al.
American Heart Journal|February 26, 2000
Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?B J O'Brien, A Willan, G Blackhouse, et al.
Archives of Internal Medicine|November 5, 1999
Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosisB O'Brien, M Levine, A Willan, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 3, 1998
Relation between severity of Alzheimer's disease and costs of caringM J Hux, B J O'Brien, M Iskedjian, et al.
Journal of the American Geriatrics Society|May 14, 1999
Economic evaluation of donepezil for the treatment of Alzheimer's disease in CanadaB J O'Brien, R Goeree, M Hux, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|July 2, 1999
The economic burden of schizophrenia in CanadaR Goeree, B J O'Brien, P Goering, et al.
Current Medical Research and Opinion|December 22, 2005
The economic burden of schizophrenia in Canada in 2004R Goeree, F Farahati, N Burke, et al.
Journal of Medical Economics|October 6, 2012
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in CanadaD Chau, D L Becker, M E Coombes, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Social Science & Medicine (1982)|May 1, 1992
The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in CanadaS Sheingold, D Churchill, N Muirhead, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 26, 2001
Economic implications of hip fracture: health service use, institutional care and cost in CanadaM E Wiktorowicz, R Goeree, A Papaioannou, et al.
BMC Research Notes|June 18, 2015
Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluationsB Tsoi, D O'Reilly, J Jegathisawaran, et al.
American Heart Journal|February 26, 2000
Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?B J O'Brien, A Willan, G Blackhouse, et al.
Archives of Internal Medicine|November 5, 1999
Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosisB O'Brien, M Levine, A Willan, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 3, 1998
Relation between severity of Alzheimer's disease and costs of caringM J Hux, B J O'Brien, M Iskedjian, et al.
Journal of the American Geriatrics Society|May 14, 1999
Economic evaluation of donepezil for the treatment of Alzheimer's disease in CanadaB J O'Brien, R Goeree, M Hux, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|July 2, 1999
The economic burden of schizophrenia in CanadaR Goeree, B J O'Brien, P Goering, et al.
Current Medical Research and Opinion|December 22, 2005
The economic burden of schizophrenia in Canada in 2004R Goeree, F Farahati, N Burke, et al.
Journal of Medical Economics|October 6, 2012
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in CanadaD Chau, D L Becker, M E Coombes, et al.
Pageof 5